Clearmind's Intranasal MEAI Formulation Shows Stronger Nasal Retention in Ex Vivo Study
Event summary
- Clearmind Medicine reported positive ex vivo mucoadhesion results for its intranasal formulation of MEAI, showing improved nasal residence time compared to a standard solution.
- The study used rabbit nasal mucosa to evaluate retention over a 30-minute period, with the new formulation consistently maintaining higher adhesion.
- Extended nasal residence is critical for maximizing MEAI absorption and therapeutic potential in treating Alcohol Use Disorder (AUD).
- Results validate Clearmind’s nasal drug-delivery platform, designed to enhance mucosal surface retention and delivery performance.
The big picture
Clearmind’s success in improving nasal retention for its MEAI formulation aligns with broader industry efforts to develop non-hallucinogenic psychedelic-based therapies. The focus on intranasal delivery reflects a strategic push toward more effective, patient-friendly treatments for AUD, an underserved market with significant unmet needs.
What we're watching
- Clinical Translation
- Whether ex vivo retention results will translate into improved efficacy and absorption in human trials.
- Competitive Edge
- How Clearmind’s mucoadhesive formulation differentiates it from competitors developing non-hallucinogenic treatments for AUD.
- Regulatory Pathway
- The pace at which Clearmind advances MEAI through clinical stages, given the need for sustained proof of therapeutic benefit.
Related topics